Rescuing drug discovery: in vivo systems pathology and systems pharmacology

The pharmaceutical industry is currently beleaguered by close scrutiny from the financial community, regulators and the general public. Productivity, in terms of new drug approvals, has generally been falling for almost a decade and the safety of a number of highly successful drugs has recently been...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Drug discovery Vol. 4; no. 12; pp. 961 - 967
Main Authors van der Greef, Jan, McBurney, Robert N
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group 01.12.2005
Subjects
Drugs
Economic aspects
Pharmaceutical industry
Pharmacology
Product development
United States
Online AccessGet full text

Cover

More Information
Summary:The pharmaceutical industry is currently beleaguered by close scrutiny from the financial community, regulators and the general public. Productivity, in terms of new drug approvals, has generally been falling for almost a decade and the safety of a number of highly successful drugs has recently been brought into question. Here, we discuss whether taking an in vivo systems approach to drug discovery and development could be the paradigm shift that rescues the industry.
ISSN:1474-1776
1474-1784
DOI:10.1038/nrd1904